NCT00345696View on ClinicalTrials.gov

1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

January 31, 2011

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Bevacizumab

5 mg/Kg intravenous, 90-60-30 minutes, every 2 weeks.

DRUG

Capecitabine

600 mg/m2, orally, every 12 hours, continuous.

DRUG

Oxaliplatine

85 mg/m2, intravenous, 2 hours infusion, every 2 weeks

Trial Locations (1)

28041

Hospital 12 de Octubre, Madrid

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Unidad Integral de Investigación en Oncología S.L.

OTHER

NCT00345696 - 1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR. | Biotech Hunter | Biotech Hunter